aflibercept 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vascular endothelial growth factor (VEGF) receptors	4916	862111-32-8

Description:

Molecule	Description
Synonyms: aflibercept eylea AVE0005 ziv-aflibercept zaltrap VEGF Trap	has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

aflibercept
eylea
AVE0005
ziv-aflibercept
zaltrap
VEGF Trap

has antiangiogenic activity; consists of the second and third Ig domains of VEGFR1 and VEGFR2, respectively, fusion to the Fc region of IgG1; putative antineoplastic agent that binds all VEGF-A isoforms; possible medicine for eye disorders

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
March 25, 2020	PMDA	Bayer Yakuhin, Ltd
Nov. 22, 2012	EMA
Nov. 18, 2011	FDA	REGENERON PHARMACEUTICALS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	629.12	29.59	186	6753	21640	63460443
Endophthalmitis	620.12	29.59	129	6810	3463	63478620
Blindness	501.15	29.59	156	6783	21543	63460540
Visual impairment	348.18	29.59	174	6765	84272	63397811
Eye inflammation	345.41	29.59	87	6852	5512	63476571
Vitreous floaters	320.40	29.59	83	6856	5883	63476200
Vitritis	294.17	29.59	56	6883	936	63481147
Non-infectious endophthalmitis	256.58	29.59	39	6900	144	63481939
Blindness transient	215.17	29.59	55	6884	3689	63478394
Blindness unilateral	205.07	29.59	59	6880	6182	63475901
Retinal haemorrhage	195.12	29.59	54	6885	4915	63477168
Anterior chamber cell	194.77	29.59	36	6903	508	63481575
Vitreous opacities	178.84	29.59	31	6908	296	63481787
Uveitis	172.10	29.59	61	6878	12492	63469591
Eye pain	160.82	29.59	77	6862	33777	63448306
Detachment of retinal pigment epithelium	159.82	29.59	29	6910	367	63481716
Death	132.00	29.59	182	6757	374199	63107884
Retinal vasculitis	128.19	29.59	28	6911	946	63481137
Vitreous haemorrhage	127.07	29.59	32	6907	2018	63480065
Subretinal fluid	124.03	29.59	24	6915	438	63481645
Vitrectomy	118.42	29.59	20	6919	161	63481922
Hypopyon	113.01	29.59	24	6915	708	63481375
Hypertension	110.84	29.59	144	6795	279159	63202924
Vision blurred	106.96	29.59	85	6854	91839	63390244
Anterior chamber inflammation	106.61	29.59	20	6919	307	63481776
Retinal oedema	102.63	29.59	22	6917	679	63481404
Vitreous disorder	100.18	29.59	16	6923	87	63481996
Keratic precipitates	97.80	29.59	17	6922	165	63481918
Proteinuria	92.24	29.59	44	6895	19101	63462982
Neutropenia	86.68	29.59	101	6838	174904	63307179
Eye haemorrhage	75.25	29.59	30	6909	8466	63473617
Age-related macular degeneration	74.41	29.59	17	6922	706	63481377
Vitreous haze	71.45	29.59	11	6928	45	63482038
Product use issue	69.70	29.59	102	6837	220418	63261665
Retinal artery occlusion	69.66	29.59	19	6920	1634	63480449
Polypoidal choroidal vasculopathy	68.39	29.59	11	6928	63	63482020
Hypertensive crisis	67.19	29.59	33	6906	15253	63466830
Iritis	65.54	29.59	21	6918	3154	63478929
Choroidal neovascularisation	64.02	29.59	13	6926	306	63481777
Intra-ocular injection complication	63.55	29.59	9	6930	17	63482066
Disease progression	60.96	29.59	71	6868	122687	63359396
Retinal pigment epithelial tear	60.63	29.59	12	6927	247	63481836
Intraocular pressure increased	59.22	29.59	23	6916	6055	63476028
Macular oedema	57.54	29.59	20	6919	3857	63478226
Retinal vascular occlusion	54.65	29.59	12	6927	415	63481668
Hypotony of eye	53.77	29.59	10	6929	146	63481937
Metamorphopsia	51.97	29.59	14	6925	1149	63480934
Visual field defect	50.67	29.59	21	6918	6540	63475543
Iridocyclitis	49.27	29.59	16	6923	2506	63479577
Vitreal cells	48.35	29.59	8	6931	56	63482027
Retinal depigmentation	47.48	29.59	10	6929	283	63481800
Macular hole	46.64	29.59	12	6927	824	63481259
Diarrhoea	44.05	29.59	174	6765	715192	62766891
Retinal vein occlusion	43.52	29.59	14	6925	2129	63479954
Retinal ischaemia	40.04	29.59	9	6930	347	63481736
Anterior chamber flare	39.47	29.59	7	6932	77	63482006
Retinal exudates	38.59	29.59	10	6929	706	63481377
Stomatitis haemorrhagic	38.33	29.59	6	6933	28	63482055
Retinal disorder	38.28	29.59	12	6927	1678	63480405
Multiple-drug resistance	38.08	29.59	16	6923	5154	63476929
Neovascular age-related macular degeneration	38.03	29.59	8	6931	225	63481858
Ocular hyperaemia	37.48	29.59	27	6912	25117	63456966
Retinal detachment	35.87	29.59	16	6923	5953	63476130
Vena cava thrombosis	35.24	29.59	12	6927	2175	63479908
Cataract	33.42	29.59	36	6903	57017	63425066
Choroidal effusion	32.34	29.59	8	6931	468	63481615
Cardiac myxoma	32.31	29.59	7	6932	227	63481856
Bacterial endophthalmitis	30.77	29.59	6	6933	114	63481969
Stomatitis	29.86	29.59	54	6885	138671	63343412

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	750.82	28.18	239	8238	15910	34932544
Endophthalmitis	416.67	28.18	108	8369	3400	34945054
Retinal haemorrhage	315.04	28.18	94	8383	4995	34943459
Eye inflammation	257.06	28.18	67	8410	2151	34946303
Polypoidal choroidal vasculopathy	242.13	28.18	41	8436	129	34948325
Vitritis	228.03	28.18	51	8426	840	34947614
Subretinal fluid	200.08	28.18	40	8437	370	34948084
Blindness	190.14	28.18	86	8391	14900	34933554
Non-infectious endophthalmitis	189.72	28.18	33	8444	127	34948327
Detachment of retinal pigment epithelium	179.13	28.18	38	8439	482	34947972
Blindness transient	177.11	28.18	50	8427	2176	34946278
Vitreous opacities	174.27	28.18	35	8442	332	34948122
Age-related macular degeneration	141.41	28.18	29	8448	308	34948146
Proteinuria	140.48	28.18	75	8402	18567	34929887
Blindness unilateral	138.20	28.18	49	8428	4493	34943961
Vitreous floaters	129.64	28.18	44	8433	3541	34944913
Retinal oedema	127.76	28.18	30	8447	618	34947836
Visual impairment	127.20	28.18	89	8388	35713	34912741
Hypertension	115.23	28.18	153	8324	136290	34812164
Eye pain	112.33	28.18	58	8419	13404	34935050
Intraocular pressure increased	112.19	28.18	44	8433	5339	34943115
Anterior chamber inflammation	110.12	28.18	23	8454	269	34948185
Disease progression	108.28	28.18	132	8345	107945	34840509
Vitrectomy	107.49	28.18	20	8457	121	34948333
Vitreous haemorrhage	105.33	28.18	34	8443	2339	34946115
Macular hole	104.75	28.18	21	8456	197	34948257
Choroidal neovascularisation	96.87	28.18	20	8457	220	34948234
Macular oedema	94.61	28.18	33	8444	2881	34945573
Colitis microscopic	93.68	28.18	31	8446	2306	34946148
Retinal pigment epithelial tear	93.59	28.18	20	8457	263	34948191
Anterior chamber cell	93.40	28.18	21	8456	354	34948100
Dry age-related macular degeneration	91.20	28.18	17	8460	104	34948350
Neutropenia	90.52	28.18	147	8330	156631	34791823
Intra-ocular injection complication	90.30	28.18	13	8464	6	34948448
Vision blurred	87.13	28.18	79	8398	45884	34902570
Proteus infection	84.16	28.18	24	8453	1082	34947372
Diarrhoea	83.21	28.18	244	8233	389668	34558786
Uveitis	82.28	28.18	39	8438	7496	34940958
Hypopyon	81.58	28.18	19	8458	377	34948077
Retinal detachment	74.91	28.18	33	8444	5358	34943096
Eye haemorrhage	68.49	28.18	29	8448	4276	34944178
Prothrombin level decreased	66.14	28.18	20	8457	1108	34947346
Retinal vasculitis	64.80	28.18	16	8461	410	34948044
Induration	64.60	28.18	19	8458	956	34947498
Vitreous disorder	62.37	28.18	12	8465	89	34948365
Necrotising fasciitis	58.97	28.18	25	8452	3697	34944757
Corneal oedema	58.50	28.18	19	8458	1332	34947122
Clostridial infection	56.27	28.18	24	8453	3603	34944851
Neovascular age-related macular degeneration	53.78	28.18	12	8465	195	34948259
Keratic precipitates	51.17	28.18	11	8466	149	34948305
Serous retinal detachment	49.82	28.18	14	8463	598	34947856
Iritis	49.41	28.18	17	8460	1424	34947030
Stomatitis	49.20	28.18	56	8421	42458	34905996
Death	48.96	28.18	208	8269	397841	34550613
Retinal artery occlusion	44.95	28.18	17	8460	1868	34946586
Neutrophilia	40.88	28.18	20	8457	4117	34944337
Macular degeneration	39.06	28.18	16	8461	2170	34946284
Drug interaction	37.97	28.18	5	8472	225941	34722513
Klebsiella infection	36.92	28.18	24	8453	8507	34939947
Mucosal inflammation	36.66	28.18	46	8431	38576	34909878
Stoma site haemorrhage	36.44	28.18	12	8465	878	34947576
Intestinal perforation	35.61	28.18	24	8453	9036	34939418
Ocular hyperaemia	34.96	28.18	26	8451	11426	34937028
Blood lactic acid increased	34.31	28.18	21	8456	6707	34941747
Retinal degeneration	33.94	28.18	10	8467	506	34947948
Retinal scar	33.92	28.18	9	8468	309	34948145
Diaphragmatic operation	33.21	28.18	6	8471	30	34948424
Skin toxicity	32.53	28.18	18	8459	4766	34943688
Visual acuity reduced transiently	32.34	28.18	7	8470	98	34948356
Retinal depigmentation	31.24	28.18	6	8471	44	34948410
Tenderness	31.22	28.18	20	8457	6914	34941540
Ocular hypertension	29.10	28.18	10	8467	834	34947620
Dysphonia	29.09	28.18	32	8445	23351	34925103
Pelvic fluid collection	28.87	28.18	7	8470	166	34948288
Hiccups	28.80	28.18	22	8455	10060	34938394
Retinal vein occlusion	28.74	28.18	12	8465	1707	34946747
Epistaxis	28.68	28.18	51	8426	58200	34890254
Vitreous detachment	28.60	28.18	10	8467	878	34947576
Anterior chamber flare	28.35	28.18	6	8471	75	34948379

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	1216.74	24.61	368	13425	29101	79701494
Endophthalmitis	794.36	24.61	191	13602	6237	79724358
Eye inflammation	534.28	24.61	139	13654	6274	79724321
Vitritis	478.21	24.61	100	13693	1694	79728901
Retinal haemorrhage	450.07	24.61	128	13665	8089	79722506
Vitreous opacities	378.03	24.61	70	13723	605	79729990
Vitreous floaters	330.66	24.61	98	13695	7158	79723437
Polypoidal choroidal vasculopathy	305.45	24.61	50	13743	187	79730408
Non-infectious endophthalmitis	288.76	24.61	50	13743	281	79730314
Blindness transient	264.17	24.61	75	13718	4701	79725894
Detachment of retinal pigment epithelium	261.44	24.61	53	13740	763	79729832
Subretinal fluid	260.42	24.61	53	13740	779	79729816
Blindness	259.38	24.61	117	13676	28266	79702329
Anterior chamber cell	259.25	24.61	54	13739	895	79729700
Blindness unilateral	240.73	24.61	79	13714	8067	79722528
Death	226.37	24.61	373	13420	566141	79164454
Eye pain	225.23	24.61	116	13677	37462	79693133
Proteinuria	220.16	24.61	109	13684	32393	79698202
Hypertension	213.97	24.61	274	13519	330718	79399877
Vitreous haemorrhage	213	24.61	60	13733	3653	79726942
Anterior chamber inflammation	212.16	24.61	42	13751	532	79730063
Uveitis	201.59	24.61	84	13709	16746	79713849
Retinal oedema	190.41	24.61	42	13751	923	79729672
Intra-ocular injection complication	188.71	24.61	27	13766	26	79730569
Intraocular pressure increased	177.84	24.61	65	13728	9140	79721455
Vitrectomy	175.08	24.61	31	13762	202	79730393
Age-related macular degeneration	173.56	24.61	39	13754	935	79729660
Neutropenia	169.95	24.61	228	13565	287482	79443113
Retinal artery occlusion	169.92	24.61	49	13744	3245	79727350
Visual impairment	169.91	24.61	135	13658	91996	79638599
Retinal vasculitis	165.94	24.61	40	13753	1313	79729282
Hypopyon	162.11	24.61	38	13755	1104	79729491
Disease progression	160.75	24.61	178	13615	184184	79546411
Vision blurred	145.51	24.61	131	13662	105767	79624828
Retinal pigment epithelial tear	141.18	24.61	29	13764	447	79730148
Vitreous disorder	139.33	24.61	26	13767	235	79730360
Choroidal neovascularisation	129.63	24.61	27	13766	447	79730148
Macular hole	120.13	24.61	28	13765	793	79729802
Diarrhoea	119.81	24.61	378	13415	880111	78850484
Keratic precipitates	112.86	24.61	23	13770	340	79730255
Vitreal cells	111.56	24.61	18	13775	60	79730535
Macular oedema	110.74	24.61	40	13753	5434	79725161
Eye haemorrhage	101.23	24.61	44	13749	9713	79720882
Retinal detachment	96.92	24.61	42	13751	9205	79721390
Colitis microscopic	90.78	24.61	42	13751	10726	79719869
Iritis	81.10	24.61	29	13764	3826	79726769
Corneal oedema	75.73	24.61	25	13768	2595	79728000
Retinal vascular occlusion	74.71	24.61	18	13775	589	79730006
Proteus infection	72.60	24.61	23	13770	2095	79728500
Vitreous haze	71.99	24.61	13	13780	96	79730499
Neovascular age-related macular degeneration	65.61	24.61	15	13778	389	79730206
Dry age-related macular degeneration	64.66	24.61	14	13779	281	79730314
Retinal depigmentation	63.31	24.61	14	13779	311	79730284
Stomatitis	61.32	24.61	99	13694	146658	79583937
Prothrombin level decreased	61.14	24.61	19	13774	1625	79728970
Anterior chamber flare	60.53	24.61	12	13781	153	79730442
Visual field defect	60.20	24.61	30	13763	9015	79721580
Visual acuity reduced transiently	59.94	24.61	13	13780	263	79730332
Multiple use of single-use product	57.87	24.61	16	13777	908	79729687
Metamorphopsia	56.86	24.61	17	13776	1276	79729319
Retinal ischaemia	55.66	24.61	15	13778	773	79729822
Retinal vein occlusion	55.16	24.61	21	13772	3302	79727293
Induration	53.92	24.61	18	13775	1934	79728661
Necrotising fasciitis	52.25	24.61	24	13769	6026	79724569
Serous retinal detachment	51.63	24.61	15	13778	1019	79729576
Clostridial infection	50.39	24.61	23	13770	5691	79724904
Dysphonia	49.58	24.61	55	13738	56817	79673778
Mucosal inflammation	49.24	24.61	63	13730	75517	79655078
Epistaxis	49.00	24.61	77	13716	111438	79619157
Hypertensive crisis	48.31	24.61	35	13758	20735	79709860
Ocular hyperaemia	46.99	24.61	39	13754	28167	79702428
Iridocyclitis	46.06	24.61	19	13774	3685	79726910
Drug interaction	44.26	24.61	9	13784	415174	79315421
Retinal disorder	41.56	24.61	15	13778	2032	79728563
Proctalgia	40.87	24.61	24	13769	9977	79720618
Retinal exudates	40.63	24.61	13	13780	1222	79729373
Pseudoendophthalmitis	39.22	24.61	7	13786	48	79730547
Retinal scar	39.14	24.61	10	13783	418	79730177
Joint swelling	38.57	24.61	3	13790	288643	79441952
Arthralgia	38.36	24.61	26	13767	571777	79158818
Nephrotic syndrome	35.91	24.61	23	13770	11151	79719444
Klebsiella infection	35.44	24.61	26	13767	15694	79714901
Intestinal perforation	35.23	24.61	27	13766	17399	79713196
Diaphragmatic operation	35.23	24.61	6	13787	30	79730565
Rash	34.09	24.61	30	13763	578328	79152267
Cataract	33.15	24.61	47	13746	62073	79668522
Vena cava thrombosis	33.14	24.61	14	13779	2881	79727714
Hiccups	33.11	24.61	21	13772	10010	79720585
Vitreous detachment	32.96	24.61	13	13780	2246	79728349
Cerebral infarction	32.82	24.61	40	13753	45636	79684959
Retinal degeneration	32.31	24.61	11	13782	1255	79729340
Neutrophilia	32.28	24.61	19	13774	7932	79722663
Stoma site haemorrhage	31.41	24.61	12	13781	1904	79728691
Pain	31.18	24.61	46	13747	703756	79026839
Retinal perivascular sheathing	31.16	24.61	6	13787	65	79730530
Diabetic retinal oedema	30.93	24.61	8	13785	351	79730244
Nasopharyngitis	30.39	24.61	4	13789	253877	79476718
General physical health deterioration	29.87	24.61	110	13683	275128	79455467
Drug intolerance	29.68	24.61	5	13788	264114	79466481
Macular fibrosis	29.61	24.61	9	13784	714	79729881
Gastrointestinal toxicity	29.35	24.61	18	13775	8091	79722504
Eye irritation	29.17	24.61	26	13767	20655	79709940
Pulmonary embolism	29.08	24.61	80	13713	171574	79559021
Ocular discomfort	28.72	24.61	15	13778	4968	79725627
Stomatitis haemorrhagic	28.65	24.61	6	13787	102	79730493
Hypotony of eye	28.43	24.61	7	13786	251	79730344
Glaucoma	28.18	24.61	25	13768	19736	79710859
Asthenia	27.77	24.61	167	13626	511522	79219073
Abdominal discomfort	27.62	24.61	5	13788	250722	79479873
Off label use	27.58	24.61	258	13535	906957	78823638
Rectal haemorrhage	27.22	24.61	48	13745	76252	79654343
Insomnia	26.77	24.61	5	13788	245165	79485430
Blood lactic acid increased	26.32	24.61	20	13773	12724	79717871
Retinal tear	26.14	24.61	10	13783	1592	79729003
Eye infection staphylococcal	25.53	24.61	6	13787	176	79730419
Palmar-plantar erythrodysaesthesia syndrome	25.41	24.61	30	13763	33104	79697491
Retinal occlusive vasculitis	24.79	24.61	5	13788	70	79730525
Conjunctival hyperaemia	24.63	24.61	13	13780	4400	79726195

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX44	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
ATC	S01LA05	SENSORY ORGANS OPHTHALMOLOGICALS OCULAR VASCULAR DISORDER AGENTS Antineovascularisation agents
MeSH PA	D020533	Angiogenesis Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D006131	Growth Inhibitors
MeSH PA	D006133	Growth Substances
FDA MoA	N0000193542	Vascular Endothelial Growth Factor Inhibitors
FDA EPC	N0000193543	Vascular Endothelial Growth Factor Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Central retinal vein occlusion with macular edema	indication	232039004
Branch retinal vein occlusion with macular edema	indication	232048009
Neovascular glaucoma	indication	232086000	DOID:1687
Macular edema due to diabetes mellitus	indication	312912001	DOID:9191
Metastasis from malignant tumor of colon	indication	314998002
Exudative age-related macular degeneration	indication	414173003	DOID:10873
Retinopathy of prematurity	indication	415297005	DOID:13025

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Vascular endothelial growth factor A	Secreted	P15692	VEGFA_HUMAN	INHIBITOR	Kd	12.30	DRUG LABEL	DRUG LABEL
Placenta growth factor	Secreted	P49763	PLGF_HUMAN	INHIBITOR	Kd	10.41	DRUG LABEL	DRUG LABEL
Vascular endothelial growth factor B	Secreted	P49765	VEGFB_HUMAN	INHIBITOR	Kd	11.72	DRUG LABEL	DRUG LABEL

External reference:

ID	Source
15C2VL427D	UNII
D09574	KEGG_DRUG
4031234	VUID
N0000184016	NUI
4031234	VANDF
4031980	VANDF
C1134659	UMLSCUI
CHEMBL1742982	ChEMBL_ID
DB08885	DRUGBANK_ID
8739	INN_ID
C533178	MESH_SUPPLEMENTAL_RECORD_UI
6786	IUPHAR_LIGAND_ID
1232150	RXNORM
186189	MMSL
192290	MMSL
28208	MMSL
28701	MMSL
d07888	MMSL
014044	NDDF
015046	NDDF
703840003	SNOMEDCT_US
714627007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ZALTRAP	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5840	SOLUTION, CONCENTRATE	100 mg	INTRAVENOUS	BLA	32 sections
ZALTRAP	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5841	SOLUTION, CONCENTRATE	200 mg	INTRAVENOUS	BLA	32 sections
EYLEA	HUMAN PRESCRIPTION DRUG LABEL	1	61755-005	INJECTION, SOLUTION	40 mg	INTRAVITREAL	BLA	30 sections
EYLEA	HUMAN PRESCRIPTION DRUG LABEL	1	61755-005	INJECTION, SOLUTION	40 mg	INTRAVITREAL	BLA	30 sections
EYLEA	HUMAN PRESCRIPTION DRUG LABEL	1	61755-005	INJECTION, SOLUTION	40 mg	INTRAVITREAL	BLA	30 sections
EYLEA HD	HUMAN PRESCRIPTION DRUG LABEL	1	61755-050	INJECTION, SOLUTION	8 mg	INTRAVITREAL	BLA	29 sections
EYLEA HD	HUMAN PRESCRIPTION DRUG LABEL	1	61755-051	INJECTION, SOLUTION	8 mg	INTRAVITREAL	BLA	29 sections